pubmed.ncbi.nlm.nih.gov

The role of phosphodiesterases in schizophrenia : therapeutic implications - PubMed

Review

The role of phosphodiesterases in schizophrenia : therapeutic implications

Judith A Siuciak. CNS Drugs. 2008.

Abstract

Recent studies have suggested that currently available antipsychotic medications, while useful in treating some aspects of schizophrenia, still possess considerable limitations. Improving the treatment of negative symptoms and cognitive dysfunction, and decreasing adverse effects remain significant challenges. Many new drug strategies have been proposed in recent years and increasing evidence suggests that members of the phosphodiesterase (PDE) gene family may play a role in the aetiology or treatment of schizophrenia. PDEs are key enzymes responsible for the degradation of the second messengers cAMP (3',5'-cyclic adenosine monophosphate) and cGMP (3',5'-cyclic guanosine monophosphate). Mammalian PDEs are composed of 21 genes and are categorized into 11 families based on sequence homology, enzymatic properties and sensitivity to pharmacological inhibitors. Representatives from most families have been identified in the brain by the presence of protein or RNA, and numerous studies suggest that PDEs play an important role in the regulation of intracellular signalling downstream of receptor activation in neurons. Insights into the multiple brain processes to which PDEs contribute are emerging from the phenotype of genetically engineered mice that lack activity of specific PDEs (knockout mice), as well as from in vitro and in vivo studies with PDE inhibitors.This article provides a brief overview of recent studies implicating PDE inhibition, focusing on PDE4 and PDE10, as targets for treating the positive, negative or cognitive symptoms associated with schizophrenia.

PubMed Disclaimer

Cited by

Identification and Localization of the Cyclic Nucleotide Phosphodiesterase 10A in Bovine Testis and Mature Spermatozoa.
Goupil S, Maréchal L, El Hajj H, Tremblay MÈ, Richard FJ, Leclerc P. Goupil S, et al. PLoS One. 2016 Aug 22;11(8):e0161035. doi: 10.1371/journal.pone.0161035. eCollection 2016. PLoS One. 2016. PMID: 27548062 Free PMC article.
Mitochondrial Oxidative Phosphorylation System (OXPHOS) Deficits in Schizophrenia: Possible Interactions with Cellular Processes.
Bergman O, Ben-Shachar D. Bergman O, et al. Can J Psychiatry. 2016 Aug;61(8):457-69. doi: 10.1177/0706743716648290. Can J Psychiatry. 2016. PMID: 27412728 Free PMC article. Review.
Mechanisms for the modulation of dopamine d(1) receptor signaling in striatal neurons.
Nishi A, Kuroiwa M, Shuto T. Nishi A, et al. Front Neuroanat. 2011 Jul 18;5:43. doi: 10.3389/fnana.2011.00043. eCollection 2011. Front Neuroanat. 2011. PMID: 21811441 Free PMC article.
A new model of Pde4d deficiency: genetic knock-down of PDE4D enzyme in rats produces an antidepressant phenotype without spatial cognitive effects.
Schaefer TL, Braun AA, Amos-Kroohs RM, Williams MT, Ostertag E, Vorhees CV. Schaefer TL, et al. Genes Brain Behav. 2012 Jul;11(5):614-22. doi: 10.1111/j.1601-183X.2012.00796.x. Epub 2012 May 8. Genes Brain Behav. 2012. PMID: 22487514 Free PMC article.
Pentoxifylline as an adjunctive in treatment of negative symptoms in chronic schizophrenia: A double-blind, randomized, placebo-controlled trial.
Abdallah MS, Mosalam EM, Hassan A, Ramadan AN, Omara-Reda H, Zidan AA, Samman WA, El-Berri EI. Abdallah MS, et al. CNS Neurosci Ther. 2023 Jan;29(1):354-364. doi: 10.1111/cns.14010. Epub 2022 Nov 7. CNS Neurosci Ther. 2023. PMID: 36341700 Free PMC article. Retracted. Clinical Trial.

References

1. Biochem J. 2002 Jan 15;361(Pt 2):211-20 - PubMed
1. Psychopharmacology (Berl). 2007 Jun;192(2):275-82 - PubMed
1. Psychopharmacology (Berl). 2005 May;179(3):613-9 - PubMed
1. Br J Pharmacol. 2002 Apr;135(7):1783-93 - PubMed
1. Rev Physiol Biochem Pharmacol. 1999;135:67-104 - PubMed

The role of phosphodiesterases in schizophrenia : therapeutic implications - PubMed